Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company

02:55 PM EDT, 09/14/2026 (MT Newswires) -- Cellectis (CLLS) shares were down nearly 40% in Monday trading after the company said it will realign its focus to become an in vivo gene editing company developing long-lasting treatments for chronic diseases. This transformation follows the "promising" preclinical proof-of-concept for its lead candidate programs -- HEAL-101 for severe hypertriglyceridemia and HEAL-201 for severe hypercholesterolemia, the company said. Cellectis will also exit development of lasme-cel and eti-cel, while seeking partnership opportunities to maximize their value, it said. Cellectis will shift resources to focus on its in vivo gene editing pipeline and support its existing cell therapy partnerships with AstraZeneca (AZN), Allogene (ALLO), Servier and Iovance (IOVA), extending its cash runway into H2 of 2028, the company said. Price: 1.87, Change: -1.23, Percent Change: -39.68